Details of the Drug

General Information of Drug (ID: DMFC0ZB)

Drug Name

PF-07242813

Indication

Disease Entry	ICD 11	Status	REF
Atopic dermatitis	EA80	Phase 1	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecule

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
T-cell surface glycoprotein CD1a (CD1A)	TTBGTFN	CD1A_HUMAN	Inhibitor	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Atopic dermatitis

ICD Disease Classification

EA80

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
T-cell surface glycoprotein CD1a (CD1A)	DTT	CD1A	6.30E-02	0.67	1.48

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

References

1	ClinicalTrials.gov (NCT04668066) A PHASE 1 FIRST IN HUMAN, RANDOMIZED, DOUBLE BLIND, SPONSOR OPEN, PLACEBO-CONTROLLED, SINGLE- AND MULTIPLE DOSE ESCALATION, PARALLEL GROUP STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF PF 07242813 IN HEALTHY PARTICIPANTS AND PARTICIPANTS WITH ATOPIC DERMATITIS. U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of Pfizer